Concentric cohesion cooperation and win-win large pharmacies hold ordering meeting and year-end thank-you meeting
Release time:
2022-12-04
News from our newspaper # February 25 , Jianfeng Pharmacy held "Concentric Strength, Win-Win Cooperation " 2022 Order Meeting and Year-End Business Thank You Meeting to enhance understanding with cooperative manufacturers, deepen friendship and explore opportunities for win-win results. At the
order meeting, the management team of the large pharmacy and the heads of the pharmacies shuttled between the booths and actively held talks with the representatives of the manufacturers. Cooperative manufacturers also take this opportunity to launch points, return gifts and other preferential activities.
Dai Jinxiao, Deputy Secretary of the Party Committee of Peak Pharmaceuticals, delivered a speech at the meeting, reviewing the impact of pharmaceutical management policies and the new coronary pneumonia epidemic on the ecology of the pharmaceutical industry over the past year, and making a vision for future development. He said that the reform of the pharmaceutical supply side, the increasingly standardized and strict medical insurance payment policy, and the continuous implementation of the state's policy to support the development of the pharmaceutical and biological industry have promoted the high-quality development of the pharmaceutical industry and helped to improve the competitiveness of the pharmaceutical retail industry. With its variety and brand advantages, Jianfeng Pharmacy will adapt to the changes in the market and customer demand, seek breakthroughs from business philosophy and ideas, and change from sales-centered to service-centered, to improve service quality, product quality, marketing quality, increase categories, improve professional service level as the starting point, attract customers, improve customer stickiness, expand sales scale. In the
event, awards were also given to cooperative enterprises with close cooperation and good results in the year. Jinhua Pharmaceutical Co., Ltd., Zhejiang Yingte Electronic Commerce Co., Ltd., East China Pharmaceutical Jinhua Co., Ltd., and Sinopharm Jinhua Co., Ltd. won the Outstanding Partner Award, Zhejiang Yingte Biological Products Marketing Co., Ltd., Zhejiang Emperor Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and AstraZeneca Pharmaceutical Co., Ltd. won the Best Strategic Cooperation Award. Xu Junxiong, general manager of
Jianfeng Pharmacy, said that Jianfeng Pharmacy has been adhering to the tenet of "serving the people wholeheartedly and health forever " and has been continuously developing and growing. 2022 Although severely affected by the epidemic, with the unremitting efforts of all employees and the support of partners, we actively sought countermeasures, continuously enriched varieties, added new cooperative enterprises, and improved service levels, and still achieved good results. In the future, Jianfeng Pharmacy will continue to develop and innovate, and work with your partners to promote the high-quality development of the pharmaceutical industry, and provide customers with cheap and high-quality products and high-quality services. (Reporter Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page